Antibodi Monoklonal CGRP untuk Mencegah Migren

Oleh :

dr. Nathania S. Sutisna

Penemuan mengenai peran calcitonin gene-related peptide (CGRP) dalam patogenesis migren membuat antibodi monoklonal anti-CGRP menjadi terapi profilaksis yang menjanjikan untuk migren. Obat yang termasuk dalam anti-CGRP adalah fremanezumab, erenumab, galcanezumab, dan eptinezumab.[1,1a]

European Headache Federation tahun 2022 telah menyatakan bahwa antibodi monoklonal CGRP direkomendasikan untuk pencegahan migren karena efektif dan aman juga dalam jangka panjang. Bukti berkualitas sedang hingga tinggi telah ditemukan untuk pemberian eptinezumab, erenumab, fremanezumab, dan galcanezumab untuk penderita migren episodik dan kronis.[1a]

Fremanezumab (TEV 48125), galcanezumab (LY 2951742), dan eptinezumab (ALD 403) adalah obat yang memiliki kemampuan untuk berikatan dengan calcitonin gene-related peptide (CGRP). Sementara itu, erenumab (AMG 334) merupakan obat yang secara selektif berpotensi menduduki reseptor CGRP.[1-4]

(Konten ini khusus untuk dokter. Registrasi untuk baca selengkapnya)

Referensi

1. Silberstein SD, Dodick DW, et al. Fremanezumab for the preventive treatment of chronic migraine. N Engl J Med, 2017;377:2113-2122
2. Sacco S, Amin FM, et al. European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention - 2022 update. J Headache Pain. 2022 Jun 11;23(1):67.
3. Walter S, Bigal ME. TEV-48125: a review of a monoclonal CGRP antibody in the development for the preventive treatment of migraine. Curr Pain Headache, 2015:19:6
4. Ashina M, Tepper S, et al. Efficacy and safety of erenumab (AMG334) in chronic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study. Cephalalgia. 2018 Sep;38(10):1611-1621.
5. Tso AR, Goadsby PJ. Anti-CGRP Monoclonal Antibodies: the next era of migraine prevention? Curr Treat Options Neurol, 2017;19(8):27
6. Weatherall MW. The diagnosis and treatment of chronic migraine. Ther Adv Chronic Dis, 2015;6(3):115-123
7. Mayans L, Walling A. Acute Migraine Headache: Treatment Strategies. Am Fam Physician. 2018 Feb 15;97(4):243-251. PMID: 29671521.
8. Peters GL. Migraine overview and summary of current and emerging treatment options. Am J Manag Care. 2019 Jan;25(2 Suppl):S23-S34. PMID: 30681821.
9. Martelletti P, Guglielmetti M. Approaching the appropriate pharmacotherapy of menstrual migraine. Expert Rev Neurother. 2020 Jan;20(1):1-2.
10. Levin M, Silberstein SD, et al. Basic considerations for the use of monoclonal antibodies in migraine. Headache: The Journal of Head and Face Pain. 2018 Nov;58(10):1689-96.
11. Goadsby PJ, Reuter U, et al. A controlled trial of erenumab for episodic migraine. N Engl J Med, 2017;377:2123-32.
12. Dodick DW, Goadsby PJ, et al. Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study. Lancet Neurol, 2014;13(9):885-92.
13. Dodick DW, Goadsby PJ, et al. Randomized, double-blind, placebo-controlled, phase II trial of ALD403, an anti-CGRP peptide antibody in the prevention of frequent episodic migraine. Lancet Neurol. 2014;13:1100–1107.
14. Messina R, Huessler EM, et al. Safety and tolerability of monoclonal antibodies targeting the CGRP pathway and gepants in migraine prevention: A systematic review and network meta-analysis. Cephalalgia. 2023 Mar;43(3):3331024231152169.